|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Access to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors that lower low-density lipoprotein cholesterol in patients at high risk of atherosclerotic cardiovascular disease events has proven challenging.
|
30745204 |
2020 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This relationship provides a basis for the use of PCSK9 inhibitors in prevention of atherosclerosis and related clinical events.
|
31746997 |
2020 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias.
|
29807195 |
2020 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
European Society of Cardiology and European Atherosclerosis Society guidelines for the management of dyslipidaemias were used for screening patients eligible for PCSK9 inhibitors.
|
31732461 |
2020 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) has revolutionized our understanding of cholesterol homeostasis and added to our arsenal against atherosclerotic cardiovascular disease (ASCVD).
|
31151804 |
2020 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amounts of studies show that proprotein convertase subtilisin/kexin type 9 (PCSK9) can increase the low-density lipoprotein cholesterol ((LDL-C), leading to the progression and development of atherosclerosis.
|
31513960 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated the role of LPAR4 in experimental atherosclerosis elicited by adeno-associated virus expressing PCSK9 to lower LDL receptor levels.
|
30796085 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.
|
31075236 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
LDL cholesterol (LDL-C) lowering drugs that operate through the inhibition of PCSK9 are being pursued for the management of hypercholesterolemia and reducing its associated atherosclerotic cardiovascular disease (CVD) risk.
|
30448414 |
2019 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in PCSK9 that strengthen its interactions with LDLR result in familial hypercholesterolemia (FH) and early onset atherosclerosis, while nonsense mutations of PCSK9 result in cardio-protective hypocholesterolemia.
|
31805108 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current scope of PCSK9 inhibitor therapy in preventive cardiology is limited to patients with familial hypercholesterolemia and/or established atherosclerotic cardiovascular disease.
|
31246589 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a promising target for treating dyslipidemia and atherosclerosis.
|
31085239 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
|
31779098 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we show that helical flow which is associated with atherosclerosis induces more PCSK9 than linear flow.
|
31593224 |
2019 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The addition of ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (i.e., evolocumab or alirocumab) to statin therapy lowers LDL-C to very low levels (≤ 30-50 mg/dL) with safety under the conditions studied and reduces the risk of recurrent cardiovascular events in patients with atherosclerotic cardiovascular disease.
|
31250329 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Humans with loss-of-function of PCSK9 exhibit exceedingly low levels of LDL-C and are protected from atherosclerosis.
|
30629143 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have shown the involvement of PCSK9 in the inflammatory pathway of atherosclerosis.
|
31236571 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present study investigated the relationship between serum PCSK9 levels and early atherosclerosis as assessed by carotid intimal-medial thickness (CIMT) and brachial-ankle pulse wave velocity (ba-PWV) in newly diagnosed type 2 diabetes mellitus (T2DM).
|
31133497 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, treatments that target PCSK9 have shown striking early efficacy and promise to improve the lives of countless patients with hyperlipidemia and atherosclerosis.
|
30767742 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to play a major role in atherosclerotic cardiovascular disease (ASCVD) by promoting hyperlipidemia.
|
30668438 |
2019 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Wild-type and D374Y-PCSK9 transgenic Yucatan minipigs were fed a high-fat, high-cholesterol diet to induce atherosclerosis and subjected to a clinical FDG-PET and computed tomography scan protocol.
|
31466620 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
|
30736965 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our <i>in vitro</i> and <i>in silico</i> study established that Ginkgolide B alleviated the Ox-LDL-induced inflammatory cascades and altered lipid metabolism in HUVECs by suppressing the PCSK-9 and, thus, could be established as a treasured alternative therapeutic candidate in the atherosclerosis management.
|
31281844 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the whole, these results demonstrate that quercetin prevents the development of AS in apoE‑/‑ mice by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1.
|
31524223 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lp(a) was measured in 25 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a randomized trial of evolocumab versus placebo in patients with established atherosclerotic cardiovascular disease (median follow-up, 2.2 years).
|
30586750 |
2019 |